La startup de edición de genes RTP, Locus Biosciences, consigue $12,5 millones de 31 inversores

Fecha de publicación:

PARQUE DEL TRIÁNGULO DE INVESTIGACIÓN — Locus Biociencias, which is developing advanced antibacterial products with gene editing technology, has raised roughly $12.5 million in debt from 31 investors, según una reciente presentación de valores.

The round, which kicked off on April 8, is capped at $15 million, with $2.5 million remaining to be sold. Funds raised will be used fo “payments of salary in the ordinary course of business,” the filing indicated.

The Morrisville-based Locus is a 2015 spinout of N.C. State University. It started with the help of a $75,000 Company Inception Loan from the North Carolina Biotechnology Center. The Biotech Center followed that with a $250,000 Small Business Research Loan a year later.

Tres de los cuatro científicos fundadores de Locus también han recibido subvenciones del Centro de Biotecnología por un total de más de $300.000.

Locus went on to raise $19 million in Series A venture capital in 2017.

This January, the startup launched the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field.

Locus ha abierto la inscripción para un ensayo de fase 1b de un tratamiento potencial para las infecciones del tracto urinario causadas por la bacteria Escherichia coli (E. coli). El estudio evaluará LBP-EC01, un “cóctel” de bacteriófagos que ha sido diseñado con la tecnología de edición de genes CRISPR Cas3 para atacar el genoma de E. coli.

In 2019, it also signed an exclusive collaboration and license agreement with Janssen Pharmaceuticals, owned by Johnson & Johnson, to develop, manufacture and commercialize crPhage products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems.

Locus received a $20 million upfront fee with an additional $798 million in payments if it meets certain development milestones.

Fuente del artículo original: WRAL TechWire